Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.25 USD | -3.68% | -3.35% | -34.43% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
Financials (USD)
Sales 2024 * | 822M | Sales 2025 * | 1.22B | Capitalization | 4.76B |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | 150M | EV / Sales 2024 * | 5.41 x |
Net cash position 2024 * | 317M | Net cash position 2025 * | 815M | EV / Sales 2025 * | 3.25 x |
P/E ratio 2024 * |
-43.1
x | P/E ratio 2025 * |
35.2
x | Employees | 704 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.68% |
Latest transcript on Apellis Pharmaceuticals, Inc.
1 day | -3.68% | ||
1 week | -3.35% | ||
1 month | -14.77% | ||
3 months | -38.57% | ||
6 months | -36.26% | ||
Current year | -34.43% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Paul R. Fonteyne
BRD | Director/Board Member | 62 | 20-04-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.61% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - | |
0.19% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 39.25 | -3.68% | 1,999,325 |
24-05-30 | 40.75 | -0.88% | 1,190,032 |
24-05-29 | 41.11 | +1.36% | 1,145,039 |
24-05-28 | 40.56 | -0.12% | 978,760 |
24-05-24 | 40.61 | +2.34% | 1,281,356 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.43% | 4.76B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- APLS Stock